Rivaroxaban Viatris (previously Rivaroxaban Mylan) Europos Sąjunga - portugalų - EMA (European Medicines Agency)

rivaroxaban viatris (previously rivaroxaban mylan)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - agentes antitrombóticos - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Sitagliptin / Metformin hydrochloride Mylan Europos Sąjunga - portugalų - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, tipo 2 - drogas usadas em diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triplo terapia de combinação), como adjuvante da dieta e exercício em pacientes inadequadamente controlados em sua máxima tolerada, a dose de metformina e uma sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Agomelatina Mylan 25 mg Comprimido revestido por película Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

agomelatina mylan 25 mg comprimido revestido por película

mylan, lda. - agomelatina - comprimido revestido por película - 25 mg - co-cristal de agomelatina e ácido cítrico 44.739 mg - agomelatine - genérico - duração do tratamento: longa duração

Ferloc-D 800 U.I. Cápsula mole Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

ferloc-d 800 u.i. cápsula mole

neogen, n.v. - colecalciferol - cápsula mole - 800 u.i. - colecalciferol 0.02 mg - colecalciferol - n/a - duração do tratamento: longa duração

Colecalciferol Neogen 1000 U.I. Cápsula mole Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

colecalciferol neogen 1000 u.i. cápsula mole

neogen, n.v. - colecalciferol - cápsula mole - 1000 u.i. - colecalciferol 0.025 mg - colecalciferol - n/a - duração do tratamento: longa duração

Osthovid 3200 U.I. Cápsula mole Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

osthovid 3200 u.i. cápsula mole

pharma bavaria internacional (pbi) portugal, unipessoal lda. - colecalciferol - cápsula mole - 3200 u.i. - colecalciferol 0.08 mg - colecalciferol - n/a - duração do tratamento: longa duração

Oxigénio Medicinal Gasin 100 % Gás medicinal comprimido Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

oxigénio medicinal gasin 100 % gás medicinal comprimido

gasin ii - gases industriais, unipessoal lda. - oxigénio - gás medicinal comprimido - 100 % - oxigénio 100 % (v/v) - oxygen - n/a - duração do tratamento: curta ou média duração

Fositen 20 mg Comprimido Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

fositen 20 mg comprimido

bausch health (ireland) limited - fosinopril - comprimido - 20 mg - fosinopril sódico 21 mg - fosinopril - n/a - duração do tratamento: longa duração

Fositen 20 mg Comprimido Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

fositen 20 mg comprimido

bausch health (ireland) limited - fosinopril - comprimido - 20 mg - fosinopril sódico 21 mg - fosinopril - n/a - duração do tratamento: longa duração

Paracetamol Pensa 500 mg Comprimido Portugalija - portugalų - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

paracetamol pensa 500 mg comprimido

towa pharmaceutical, s.a. - paracetamol - comprimido - 500 mg - paracetamol 500 mg - paracetamol - genérico - duração do tratamento: curta ou média duração